M&A / Deals Eli Lilly doubles down on in vivo with $7bn Kelonia buyout Pharmaceutical TechnologyLilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.M&A / DealsGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company’s chance of success. M&A / DealsGene Therapy PlatformRead full story Post navigation Previous: Asahi Kasei acquires German company AicurisNext: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
